Symbiont, the market-leading smart contracts platform for institutional applications of distributed ledger technology, has appointed renowned cryptographer Dr. Lisa Yin as its Chief Security Officer and Chief Cryptographer.
In her new role, Dr. Yin will lead the development of advanced security and privacy solutions of Symbiont's platform.
"The Symbiont team has already solved hard problems that give its platform a competitive edge in terms of both security and performance," said Dr. Yin. "I am very excited to join the team, and I look forward to keeping Symbiont ahead of the curve on developments in cryptography, which is a critical building block for distributed ledger technology."
Dr. Yin has over twenty years of experience in research, implementation, consulting and standardization of cutting-edge security technologies, and is a well-known expert in the cryptography community. She was one of three researchers who broke SHA-1, the U.S. Government hash standard. She served as Chief Editor of IEEE P1363, the first comprehensive standard for public key cryptography, which became the foundation for major cryptography standards used today. She received her Ph.D. in Applied Mathematics from the Massachusetts Institute of Technology.
“Cryptography and computer security are extremely fast-moving fields, so it is imperative to be able to take full advantage of the latest developments, to anticipate and proactively address new forms of attacks,” said Adam Krellenstein, CTO and co-founder of Symbiont. “Lisa’s deep knowledge in cryptography and her broad connections to the research community and the industry will allow us to leverage a wide spectrum of expertise in the fields.”
Symbiont is providing the technology for the most complex, multi-party distributed ledger pilot project to date--syndicated loans--which incorporates strict privacy requirements to keep information confidential among parties sharing data on-ledger. Credit Suisse announced completion of milestones in the project in September, which involves 15 financial institutions and includes Symbiont’s joint venture partner, Ipreo, and R3.